Reported results
- Cash, cash equivalents and marketable securities were $461.7 million as of September 30, 2026.
- Research and development expenses were $71.8 million for the three months ended September 30, 2026.
- General and administrative expenses were $18.7 million for the three months ended September 30, 2026.
- Net loss attributable to common stockholders was $86.1 million for the third quarter of 2026.
- Net cash used in operating activities was $224.0 million for the nine months ended September 30, 2026.
Guidance
- Eikon expects its current cash, cash equivalents, and marketable securities to fund operations into the first quarter of 2028.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
